10 Best Small-Cap Stocks Ready To Explode

3. Immunocore Holdings plc (NASDAQ:IMCR)

Analyst Upside Potential: 121.59%

Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company based in the United Kingdom that focuses on developing innovative treatments for various diseases, primarily using a technology called T cell receptor (TCR) bispecific immunotherapies. This technology aims to harness and enhance the body’s immune system to fight against diseases like cancer, autoimmune disorders, and infectious diseases.

KIMMTRAK is the lead product of Immunocore Holdings plc (NASDAQ:IMCR), the product has been approved for treating a specific type of eye cancer called unresectable or metastatic uveal melanoma. It is currently available in the United States and the European Union.

During the third quarter of 2024, the KIMMTRAK net revenue improved 28% year-over-year to reach $80.2 million, driven by higher demand in the United States and Germany. The growth was also aided by 11 new launches during the year aimed at expanding patient reach for the drug. To date, the product has been approved in 38 countries and has been launched in 21 countries globally.

Immunocore Holdings plc (NASDAQ:IMCR) has a robust pipeline of products currently in the clinical stage including brenetafusp, which is a treatment for melanoma, a type of skin cancer. Brenetafusp is in Phase 3 trials and is set to start randomizing patients in the fourth quarter of 2024.

Analysts’ 12-month median price target for the stock is pointing towards a 121.59% upside from current levels, thereby making it one of the best small-cap stocks ready to explode.